Patients will receive 3-day treatment with chloroquine and 7-day treatment with primaquine in accordance to treatment guidelines in Brazil for P vivax malaria. All patients will receive the same treatment as there is no comparison arm.

Patients will receive 3-day treatment with chloroquine and 7-day treatment with primaquine in accordance to treatment guidelines in Brazil for P vivax malaria. All patients will receive the same treatment as there is no comparison arm.
Chloroquine: Patients will receive 3-day treatment with chloroquine in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
Primaquine: Patients will receive 7-day treatment with primaquine, in conjunction with chloroquine, in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.

Chlorquine and Primaquine

Sex: Female, Male

Region of Enrollment

Investigators, according to WHO guidelines, will evaluate patients at regular intervals to evaluate symptom and parasitemia clearance.

Number of Patients With Adequate Clearance of Parasites and Symptoms

Evaluate the relapse rate, that is reappearance of parasites, for up to 6 months after treatment.

Number of Patients Reporting Relapses

Chloroquine and Primaquine

Overall Study

Alexande Macedo de Oliveira

Malaria

Patients will receive 3-day treatment with chloroquine in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.

Chloroquine

Patients will receive 7-day treatment with primaquine, in conjunction with chloroquine, in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.

baccharis crispa/antifungal

Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht